Actually they PR'd reception of the devices back in November, so more like they received the first devices several months, not weeks ago. And they are still well within the timeframe they publicised in LXGTF's material posted on their own website for FDA approval and commercialisation. If some poster here on the board were overenthusiastic in their projections of the time it would take to FDA clearance that shows how getting carried away in your enthusiasm for a worthy product can make you skip a few beats. LXGTF has been keeping us updated on the consulting they have been engaged to assure medical coverage compliance and that they have retained Diablo Research. And preparing the application for the IRB approval to commence testing on human subjects doesn't sound as easy as writing a home class book report either.So I think they have been keeping their nose to the grind stone. As far as working on the HeartSentry device for 15 year? No one has said that. The kind of tech, such as bluetooth uploading of data to the cloud for analysis, didn't even exist back then. Now the science behind endthelial diagnostics and the link to cardiavascular disease and stroke, that does go back 15 years. Johnathan Maltz, principal inventor of HeartSentry and Chief Science Advisor to LXGTF, spearheaded a lot of that at Berkely labs. But thats the pace of doing groundbreaking, paradigm shifting, peer-reviewed research on the modern biomedical research scene. Its the way modern medicine works. It may seem painstakingly slow, but would you really want biomedical companies to start sacrificing the scientific method to get to market faster? All that being said, once again, $LXGTF itself is well within the timeframe they posted in the literature on their website. 2018 should be a great year for them and for us investors.
